Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis  by McNally, P. et al.
Journal of Cystic Fibrosis 10 (2011) 428–434
www.elsevier.com/locate/jcfOriginal Article
Vitamin D receptor agonists inhibit pro-inflammatory cytokine production
from the respiratory epithelium in cystic fibrosis☆
P. McNally a, d,⁎, C. Coughlan d, G. Bergsson d, M. Doyle b, C. Taggart d, L. Adorini c,
M.R. Uskokovic c, B. El-Nazir a, P. Murphy b, P. Greally a, C.M. Greene d, N.G. McElvaney d
a Department of Paediatric Respiratory Medicine, Adelaide and Meath Hospital incorporating the National Children's Hospital, Dublin 24, Ireland
b Department of Microbiology, Adelaide and Meath Hospital incorporating the National Children's Hospital, Dublin 24, Ireland
c Bioxell SpA, Milano, Italy
d Respiratory Research Division, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland
9 March 2011; 11 June 2011; 28 June 2011
Available online 23 July 2011Abstract
Background: 1,25-Dihydroxycholecalciferol (1,25(OH)2D3) has been shown to mitigate epithelial inflammatory responses after antigen exposure.
Patients with cystic fibrosis (CF) are at particular risk for vitamin D deficiency. This may contribute to the exaggerated inflammatory response to
pulmonary infection in CF.
Methods: CF respiratory epithelial cell lines were exposed to Pseudomonas aeruginosa lipopolysaccharide (LPS) and Pseudomonas conditioned
medium (PCM) in the presence or absence of 1,25(OH)2D3 or a range of vitamin D receptor (VDR) agonists. Levels of IL-6 and IL-8 were
measured in cell supernatants, and cellular total and phosphorylated IκBα were determined. Levels of human cathelicidin antimicrobial peptide
(hCAP18) mRNA and protein were measured in cells after treatment with 1,25(OH)2D3.
Results: Pretreatment with 1,25(OH)2D3 was associated with significant reductions in IL-6 and IL-8 protein secretion after antigen exposure, a
finding reproduced with a range of low calcaemic VDR agonists. 1,25(OH)2D3 treatment led to a decrease in IκBα phosphorylation and increased
total cellular IκBα. Treatment with 1,25(OH)2D3 was associated with an increase in hCAP18/LL-37 mRNA and protein levels.
Conclusions: Both 1,25(OH)2D3 and other VDR agonists significantly reduce the pro-inflammatory response to antigen challenge in CF airway
epithelial cells. VDR agonists have significant therapeutic potential in CF.
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Individuals with CF develop abnormal electrolyte transport in
several organs, leading to the accumulation of viscid secretions at
epithelial surfaces. In the lungs, this results in the development of
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doi:10.1016/j.jcf.2011.06.013and ultimately respiratory failure [1]. InfectionwithP. aeruginosa
is associated with increased morbidity and mortality.
1,25-Dihydroxycholecalciferol (1,25(OH)2D3) is the biologi-
cally active form of the secosteroid hormone vitamin D.
Originally described as being essential for maintenance of bone
and mineral homeostasis, it has subsequently been discovered to
have many other functions including immune system modulation
[2]. 1,25(OH)2D3 has been shown to downregulate monocyte toll
like receptor (TLR) expression, trigger hyporesponsiveness to
pathogen associated molecular patterns (PAMPs) [3] and reduce
co-stimulatory molecule and MHC II expression in monocytes
and dendritic cells [4–7]. In addition to this, 1,25(OH)2D3 has
significant effects on function and signalling within T celld by Elsevier B.V. All rights reserved.
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inflammatory effects of antigenic stimulation at epithelial
surfaces. For example, in human corneal epithelial cells, 1,25
(OH)2D3 can decrease basal levels of IL-1β, IL-1α and IL-8
production [11], and decrease the secretion of IL-1β, IL-6 and
IL-8 after challenge with Pseudomonas aeruginosa [12]. In
human microvessel endothelial cells, pretreatment with 1,25
(OH)2D3 inhibits LPS induced NF-κB activation and IL-6, IL-
8 andRANTES release [13]. 1,25(OH)2D3 has also been shown to
induce indirect antimicrobial actions in a number of different cell
and tissue types by virtue of its ability to upregulate expression
and secretion of the antimicrobial peptide LL-37 [14–18].
Recently, 1,25(OH)2D3 deficiency has been linked with allergic
bronchopulmonary aspergillosis in individuals with CF [19].
Several studies have demonstrated low levels of vitamin D
(25(OH)D) in infants, children and adults with CF [20–24].
This is likely related to the high prevalence of fat soluble
vitamin malabsorption, impaired hydroxylation of vitamin D
and reduced sun exposure [23]. It has been shown that vitamin
D levels tend to decrease with age in patients with CF, and low
levels are more common in adolescents than in younger children
[25]. Most patients with CF require oral supplementation to
avoid vitamin D deficiency.
Given the abnormalities in airway epithelial innate defence
in CF, in particular the excessive nature of the inflammatory
response to infection, and in light of the role played by vitamin
D in modulation of innate defence and inflammatory responses,
we sought to examine the ability of vitamin D and a panel of
VDR agonists to modulate the inflammatory response of the CF
respiratory epithelium to pathogen challenge.
2. Methods
2.1. Tissue culture and treatments
All cell lines were maintained in a 37 °C, humidified 5% CO2
incubator in appropriate media. CFBE41o−, CFTE29o− (human
ΔF508 homozygote bronchial and tracheal epithelial cell lines,
respectively) were obtained as a gift from D. Gruenert (California
Pacific Medical Center Research Institute, San Francisco, CA)
[26,27]. Cell lines were grown in MEM+10% FCS (v/v) with 1%
(v/v) penicillin and streptomycin (Invitrogen). Cells were grown to
confluency and seeded at either 1×105/1×106 cell/ml for RNA or
protein expression studies respectively. To eliminate the effect of
different factors in the growthmedia, 24 h prior to stimulation, cells
were washed and placed under serum-free conditions. Pseudomo-
nas LPS was re-constituted according to manufacturers' in-
structions in 1% media and added to CF epithelial cells for 24 h
at various concentrations. 1,25-dihyroxyvitamin D3 (Biomol
International, Inc) was prepared to a working concentration of
60 mM in ETOH. A further concentration of 0.01 μM was
prepared in serum free media/1% media and added to confluent
CFTE29o−/CFBE41o− cells for a 24 hour incubation period.
P. aeruginosa strain 01 (PAO1) conditioned medium (PCM) was
prepared by filter sterilising supernatants taken from PAO1
trypticase soy broth cultures at 72 h. 50 μl equivalent to 5% (v/v)
was added to confluent CFBE41o−, CFTE29o− for 24 h.2.2. Quantitative RT-PCR analysis of gene expression
Total RNAwas extracted using Tri Reagent, equal quantities of
which were reverse transcribed into cDNA using Quantitect
Reverse Transcription Kit (Qiagen, Valencia, CA) following the
manufacturer's protocol. The following primers were used for
GAPDH: Forward 5′-CATGAGAAGTATGACAACAGCCT-3′,
Reverse 5′-AGTCCTTCCACGATACCAAGT-3′. LL-37 primers
used in this study (Forward 5′-GATGGATGGGGACCCAGA-
3′, Reverse 5′-CCT GGT TGA GGG TCA C GT-3′) to determine
gene expression levels were obtained from MWG Eurofins
Genetics. qRT-PCR was performed on the Roche LC480 Light-
cycler. Expression of the desired gene relative to GAPDH was
determined using the 2(−ΔΔCt) method. All qRT-PCR experiments
were performed in triplicate, including non-template controls.2.3. Western blots
Western blots for vitamin D receptor and hCAP18/LL-37 were
carried out as follows: samples were separated by electrophoresis
on a 12.5% (w/v) SDS polyacrylamide gel and transferred to a
nitrocellulose membrane at 100 mAmps for 1 h. Membranes were
blocked in 5% (w/v) marvel at room temperature for 1 h. PVDF
membranes (Roche) were probed using a rabbit polyclonal Ab to
LL-37 (1:1000 dilution) (Innovagen, Sweden) or 1:3000 rat anti-
vitamin D receptor (VDR) (Chemicon) and incubated overnight at
4 °C. Signals were detected using the appropriate HRP-conjugated
secondary antibody (Cell Signalling Technologies, Beverly, MA)
and visualised by chemiluminescence (Pierce, Rockford, IL) on the
Syngene G: Box chemi XL gel documentation system.2.4. ELISA
IL-6 and IL-8 were measured by ELISA using 1:250 mouse
anti-IL-6 and 1:125 mouse anti-IL-8 as primary antibodies, IL-6
and IL-8 protein standards and 1:2500 biotinylated goat anti-IL-
6 and 1:2500 biotinylated goat anti-IL-8 as detection antibodies
(all R&D systems, Abingdon, Oxon, UK).2.5. Quantification of total and phosphorylated IκBα in
CFTE29o− cells
Cellular levels of total and phosphorylated IκBα produced
under different experimental conditions were assayed by ELISA
using the CASE® assay kit (SABiosciences) as per manufac-
turer's instructions.2.6. VDR agonists
VDR agonists were synthesised by Dr Milan Uskokovic,
Bioxell, Nutley, NJ. All were N95% pure. VDR agonists were
used in the same molar concentration as 1,25(OH)2D3 in all
experiments. Five agonists were used, coded A1–A5 as follows:
A1 (BXL-01-0062), A2 (RO-27-5646), A3 (BXL-01-0072), A4
(BXL-01-0097) and A5 (BXL-01-0118).
Fig. 2. IL-8 concentrations in the supernatants of CFTE (A) and CFBE (B) cells
after treatment with either 1% media (control), LPS (1%) or Pseudomonas
PAO1 culture media (1%). The cells were either untreated or pre-treated (for 1 h)
with 1,25(OH)2D3. Assays were preformed in duplicate, 3 times. All results are
shown. Error bars reflect standard error of the mean. Differences in individual
means were assessed by Student's t test.
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Serum 25 hydroxyvitamin D (25OHD) was measured in
serum with a radioimmunoassay kit as per manufacturer's
instructions (DiaSorin, Saluggia, Italy).
2.8. Statistics
Data were analysed using GraphPad PRISM 4.0 software.
Results are expressed as the mean±SE. Differences were
considered significant at p≤0.05. Continuous data were tested
for normality (Kolmogorov–Smirnoff test) and where normal
were compared using a Student t-test paired or unpaired where
appropriate.
3. Results
3.1. Vitamin D receptor is expressed in CFTE29o− cells and is
inducible by 1,25(OH)2D3
In an effort to assess the presence and inducibility of nuclear
vitamin D receptor (VDR) in CF tracheal epithelial cells,
CFTE29o− cells were treated for up to 4 h with 1,25(OH)2D3.
Fig. 1 demonstrates the presence of VDR in the nuclei of resting
CFTE cells. Treatment with 10−9 M 1,25(OH)2D3 resulted in
increasing intensity of the nuclear VDR band up to 4 h. Equal
protein loading was confirmed by staining with Ponceau S (data
not shown).
3.2. 1,25(OH)2D3 inhibits pro-inflammatory cytokine release
from stimulated CF respiratory epithelial cells
Having confirmed expression and inducibility of nuclear
VDR in CFTE29o− cells, we sought to determine whether pre-
treating these cells with 1,25(OH)2D3 prior to challenge with aFig. 1. A) Western blot for vitamin D receptor (VDR) in cytoplasm (C) and nucleus
(N) of CFTE cells at baseline (CTR) and after 10 min, 30 min, 1 h, 2 h and 4 h of
incubation with 10−9 M 1,25(OH)2D3. The experiment was repeated 3 times. A
representative blot is shown. B) Densitometric analysis of the blot in A.microbial antigen would alter the inflammatory response. Fig. 2
shows significant reduction in the secretion of IL-8 in response
to both LPS and PCM in cells pre-treated with vitamin D. This
is shown in CFTE cells and confirmed in CFBE cells. In a
further experiment, CFTE29o− cells were pretreated with either
10−9 M 1,25(OH)2D3 or control, and then incubated with
varying doses of LPS for up to 24 h. LPS induced IL-8 release
was time and dose-dependent (Fig. 3A). Pre-treatment with 1,25
(OH)2D3 was associated with lower IL-8 production in response
to LPS at all time points and doses of LPS. This was particularly
apparent at 1 μg/ml LPS (Fig. 3A). A similar pattern was noted
with respect to IL-6 as seen in Fig. 3B.
3.3. VDR agonists inhibit pro-inflammatory cytokine release
from lipopolysaccharide stimulated CFTE29o− cells
Having seen the effect of 1,25(OH)2D3 on the production
of inflammatory mediators in the CF respiratory epithelium,
we next evaluated the potential therapeutic applications. A
limiting factor in the therapeutic use 1,25(OH)2D3 is the
potential for hypercalcaemia. Analogues of activated vitamin D
(VDR agonists) with a lower potential to cause hypercalcaemia
while maintaining or enhancing anti-inflammatory effects have
been developed and are being tested in various inflammatory
Fig. 3. Mean A) IL-8 and B) IL-6 levels in the supernatants of CFTE cells after
treatment with 0, 0.1, 0.5 or 1.0 μg/ml LPS for 4 h, 8 h or 24 h. The cells were either
pre-treated (for 1 h) with 10−9 M 1,25(OH)2D3 or untreated. Assays were performed
in duplicate 3 times. All results are shown. Error bars reflect standard error of the
mean. Differences in individual means were assessed by Student's t test.
Fig. 4. Relative IL-8 (A) and IL-6 (B) concentrations in the supernatants of
CFTE cells after treatment with 1.0 μg/ml LPS for 4 h (relative to controls). The
cells were either untreated or pre-treated (for 1 h) with 1,25(OH)2D3, or the
VDR agonists A1–A5 at 10−9 M. Assays were performed in duplicate 3 times.
All results are shown. Error bars reflect standard error of the mean. Differences
in individual means were assessed by Student's t test. Differences in means
between the groups were assessed by ANOVA.
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molecular weights of the vitamin D receptor agonists used here.
Fig. 4A shows that these agonists produced a similar level
of inhibition of IL-8 release after LPS challenge compared toTable 1
1,25(OH)2D3 and VDR agonists, their chemical structures, molecular weights.
No. Code Chemical name
1,25(OH)2D3 1,25-Dihydroxy
A1 BXL-1-0062 1,25-Dihydroxy
cholecalciferol
A2 RO 27-5646 1,25-Dihydroxy
cholecalciferol
A3 BXL-1-0072 1,25-Dihydroxy
trifluoro-butyny
A4 BXL-1-0097 1,25-Dihydroxy
trifluoro-butyny
A5 BXL-1-0118 1,25-Dihydroxy
3-hydroxy-4-tri
hexafluoro-19-n1,25(OH)2D3. In the case of IL-6, Fig. 4B shows that agonists A3,
A4 and A5 are more potent inhibitors of LPS-induced IL-6
secretion than 1,25(OH)2D3. With the exception of agonist A5,
which is slightly more calcaemic than 1,25(OH)2D3, all the other
agonists tested are equally or less calcaemic than 1,25(OH)2D3
(data not shown)(Table 1). In particular, agonist A1 is 3-fold
and agonist A2 10-fold less calcaemic than 1,25(OH)2D3,
indicating awider therapeutic windowof these agonists compared
to 1,25(OH)2D3.MW
cholecalciferol 417
-16-ene-20-cyclopropyl- 427
-21(3-hydroxy-3-methyl-butyl)- 491
-21(3-hydroxy-3-trifluomethyl-4-
l)-26,27-hexadeutero-19-nor-20S-cholecalciferol
601
-21(3-hydroxy-3-trifluomethyl-4-
l)-26,27-hexadeutero-19-nor-20R-cholecalciferol
601
-20R-methyl-21-(3-trideuteromethyl-
deuterobutyl)-23E-ene-26,27-
or-cholecalciferol
617
Fig. 5. Relative absorbance values reflecting concentrations of total cellular
IκBα from CASE® assay (relative to controls at Time 0). Wells containing
CFTE cells were treated with LPS 1 μg/ml or control, in the presence or absence
of 10−9 M 1,25(OH)2D3. Differences in mean values were measured between 1)
control and 1,25(OH)2D3, 2) control and LPS and 3) LPS and LPS with 1,25
(OH)2D3. Assays were performed in duplicate twice. All results are shown.
Error bars reflect standard error of the mean. Differences in individual means
were assessed by Student's t test.
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after LPS challenge leading to higher intracellular IκBα levels
In studies using mouse macrophages and fibroblasts, a direct
increase in IκBα protein levels in the cytoplasm upon treatment
with 1,25(OH)2D3 has been demonstrated [29–31]. In order to
investigate whether a similar mechanism occurred in CFTE29o−
cells, we employed a CASE® assay specific for IκBα. Fig. 5
shows total IκBα levels expressed relative to those of the control
cells at the start of the experiment. At 60, 90 and 120 min there is a
significant increase in IκBα levels when cells are treated withFig. 6. Relative absorbance values reflecting concentrations of cellular phospho-
IκBα from CASE® assay (relative to controls at Time 0). Wells containing
CFTE cells were treated with LPS 1 μg/ml, in the presence or absence of 10−9 M
1,25(OH)2D3. Differences in mean values were measured between 1) control
and 1,25(OH)2D3, 2) control and LPS and 3) LPS and LPS with 1,25(OH)2D3.
Assays were performed in duplicate twice. All results are shown. Error bars
reflect standard error of the mean. Differences in individual means were assessed
by Student's t test.1,25(OH)2D3 alone (light grey bars). Treatment with LPS from
P. aeruginosa led to a significant decrease in IκBα levels (dark
grey bars) compared to control and this effect was inhibited by
pre-treatment with 1,25(OH)2D3 (black bars). Fig. 6 shows
relative levels of phospho-IκBα over time after LPS treatment.
Treatment with 1,25(OH)2D3 reduces production of phospho-
IκBα in control cells (light grey bars). Treatment with LPS leads
to an increase in phospho-IκBα (dark grey bars) compared to
controls, an effect that is mitigated by 1,25(OH)2D3 pre-treatment
(black bars), particularly at the earlier time points, indicating an
inhibition of IκBα phosphorylation by 1,25(OH)2D3.
3.5. Induction of hCAP18/LL-37 by 1,25(OH)2D3 in CFTE cells
Having confirmed an anti-inflammatory effect in our cell lines,
we sought to determine whether 1,25(OH)2D3 could also
potentially promote antimicrobial action by inducing the
production of the antimicrobial peptide hCAP18/LL-37. LL-37
has antimicrobial activity against P. aeruginosa and has been
shown to be induced by 1,25(OH)2D3 in other CF cell lines [14].
Fig. 7 shows an increase in both hCAP18/LL-37 mRNA and
protein production in the presence of 1,25(OH)2D3.
4. Discussion
Several investigators have demonstrated the ability of 1,25
(OH)2D3 to modulate the inflammatory response to antigen
challenge at epithelial surfaces [12,13,32]. We show in this paper
that 1,25(OH)2D3, significantly reduces the secretion of a number
of important inflammatory mediators in antigen stimulated CF
respiratory epithelial cells. We also demonstrate a potential
mechanism whereby 1,25(OH)2D3 can inhibit the phosphoryla-
tion of IκBα. We demonstrate a similar or greater effect on IL-Fig. 7. (A) Western blot for L-37 in CFTE cells (1×106) under control
conditions and after incubation for 24 h with 1,25(OH)2D3. (B) Expression
levels of hCAP18/LL-37 mRNA normalised to GAPDH in CFTE cells in the
presence and absence of 1,25(OH)2D3.
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thatmay have potential therapeutic implications. Furthermore, we
confirm in our cell line the induction of the antimicrobial protein
hCAP18/LL-37 by 1,25(OH)2D3.
1,25(OH)2D3 has been shown to inhibit IκBα phosphorylation
and cause a direct increase in IκBα protein levels in the cytoplasm
of murine macrophages, fibroblasts, and pancreatic islet cells,
resulting in reduced NF-κB nuclear translocation [29,30,33,34].
We confirm that this effect on IκBα protein levels occurs also in
the CF respiratory epithelium, providing a mechanism whereby
1,25(OH)2D3 may exert at least part of its anti-inflammatory
effect in CF. From the point of view of cystic fibrosis, this is
important given the role of proinflammatory mediators, particu-
larly IL-8, in the inflammatory response at the respiratory
epithelium.Our finding of increased expression and production of
LL-37 by vitamin D in our cell line, while not novel, further
underlines the potential beneficial effects of vitamin D on
pathogen driven inflammation at the CF respiratory epithelium.
A link between vitamin D deficiency and chronic lung disease
is becoming increasingly clearer [35]. As part of a national adult
health survey in the US, low levels of 25(OH)D were strongly
linked to lower FEV1 and FVC after adjustment for other
variables [36]. Low serum 25(OH)D levels have also been
associated with an increased incidence of acute respiratory
symptoms and lower respiratory infection [37,38]. Wolfenden
et al. [39] demonstrated a correlation between FEV1 and vitamin
D levels in adults with CF after correcting for other variables,
although this has not been demonstrated in children with CF [25].
Vitamin D deficiency is common in CF and increases with age
during childhood [25]. Optimisation of vitamin D levels is one of
the many targets of treatment in CF. Patients are told that the
principle reason for this is the desire to optimise bone mineral
status. Many clinicians report poor compliance with vitamin
supplements in patients with CF, and studies have shown that
compliancewith vitamin supplementation is often poorer thanwith
other forms of treatment including respiratory treatments,
particularly in people with lower lung function [40–42]. This
may relate to lower perceived importance for vitamins compared to
respiratory treatments. In light of the link between vitamin D levels
and lung function both in the general population and in individuals
with CF, and taking into consideration our findings, we feel that the
potential importance of vitamin D supplementation for lung health
among peoplewithCF should clearly be communicated to patients.
In light of the potential for hypercalcaemia with significant
systemic exposure to 1,25(OH)2D3, several investigators have
developed VDR agonists with a decreased potential to cause
hypercalcaemia. A wide range of these agonists exists. VDR
agonists (not the specific agents used in this study) have been
used in secondary hyperparathyroidism with success [43], and
are currently being tested in a number of cancers [44]. In our in-
vitro system, a range of low calcaemic VDR agonists showed
similar or greater suppression of pro-inflammatory cytokine
production after P. aeruginosa LPS challenge compared to 1,25
(OH)2D3. An agent with potential to dampen the excessive
cytokine and chemokine responses of the CF respiratory
epithelium to infectious stimuli holds great therapeutic potential
for patients with CF.This work has demonstrated the ability of 1,25(OH)2D3 and
a range of VDR agonists to mitigate the inflammatory response
to infection in CF respiratory epithelial cells. Given the marked
anti-inflammatory effect at the respiratory epithelium that we
have demonstrated, and the uncertainty of local airway
concentration after systemic administration, direct airway
deposition of low calcaemic VDR agonists by inhalation may
hold therapeutic potential.References
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